Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)
Autonomix Medical (NASDAQ: AMIX) announced that its abstract on nerve-targeted treatment technology and early proof-of-concept study results has been accepted for poster presentation at the 2025 European Conference on Interventional Oncology (ECIO). The presentation, titled 'Catheter-Based Transvascular RF Neural Ablation for Severe Pancreatic Cancer Pain: First Results from The Elpis Study,' will be presented at the conference scheduled for April 13-16, 2025, in Rotterdam, Netherlands. The study's authors include Dr. Robert S. Schwartz, Chief Medical Officer of Autonomix Medical, and Dr. Askar Uktamovich Sabirov from AKFA Medline Hospital.
Autonomix Medical (NASDAQ: AMIX) ha annunciato che il suo abstract sulla tecnologia di trattamento mirato ai nervi e i risultati preliminari dello studio di prova di concetto sono stati accettati per una presentazione poster alla 2025 European Conference on Interventional Oncology (ECIO). La presentazione, intitolata 'Ablazione Neurale RF Transvascolare con Catetere per il Dolore Grave da Cancro Pancreatico: Primi Risultati dello Studio Elpis,' sarà presentata durante la conferenza programmata dal 13 al 16 aprile 2025 a Rotterdam, Paesi Bassi. Gli autori dello studio includono Dr. Robert S. Schwartz, Direttore Medico di Autonomix Medical, e Dr. Askar Uktamovich Sabirov dell'ospedale AKFA Medline.
Autonomix Medical (NASDAQ: AMIX) anunció que su resumen sobre la tecnología de tratamiento dirigida a nervios y los resultados iniciales del estudio de prueba de concepto han sido aceptados para una presentación en póster en la 2025 European Conference on Interventional Oncology (ECIO). La presentación, titulada 'Ablación Neural RF Transvascular con Catéter para el Dolor Severo por Cáncer de Páncreas: Primeros Resultados del Estudio Elpis,' se presentará en la conferencia programada del 13 al 16 de abril de 2025 en Rotterdam, Países Bajos. Los autores del estudio incluyen a Dr. Robert S. Schwartz, Director Médico de Autonomix Medical, y Dr. Askar Uktamovich Sabirov del Hospital AKFA Medline.
Autonomix Medical (NASDAQ: AMIX)는 신경 표적 치료 기술과 초기 개념 증명 연구 결과에 대한 초록이 2025 유럽 중재 종양학 회의 (ECIO)에서 포스터 발표로 수락되었다고 발표했습니다. '심각한 췌장암 통증을 위한 카테터 기반 혈관내 RF 신경 절제: 엘피스 연구의 첫 결과'라는 제목의 발표는 2025년 4월 13일부터 16일까지 네덜란드 로테르담에서 열리는 회의에서 진행될 예정입니다. 이 연구의 저자에는 Dr. Robert S. Schwartz, Autonomix Medical의 최고 의료 책임자, 및 Dr. Askar Uktamovich Sabirov가 포함되어 있습니다. AKFA Medline 병원 소속입니다.
Autonomix Medical (NASDAQ: AMIX) a annoncé que son résumé sur la technologie de traitement ciblé des nerfs et les résultats préliminaires de l'étude de preuve de concept ont été acceptés pour une présentation sous forme de poster lors de la 2025 European Conference on Interventional Oncology (ECIO). La présentation, intitulée 'Ablation Neurale RF Transvasculaire par Cathéter pour la Douleur Grave du Cancer du Pancréas : Premiers Résultats de l'Étude Elpis,' sera présentée lors de la conférence prévue du 13 au 16 avril 2025 à Rotterdam, aux Pays-Bas. Les auteurs de l'étude incluent Dr. Robert S. Schwartz, Directeur Médical d'Autonomix Medical, et Dr. Askar Uktamovich Sabirov de l'hôpital AKFA Medline.
Autonomix Medical (NASDAQ: AMIX) gab bekannt, dass sein Abstract zur nervenfokussierten Behandlungstechnologie und den frühen Ergebnissen der Machbarkeitsstudie für eine Posterpräsentation auf der 2025 European Conference on Interventional Oncology (ECIO) akzeptiert wurde. Die Präsentation mit dem Titel 'Katheterbasierte transvasale RF-Neuralablation bei schwerem Bauchspeicheldrüsenkrebs-Schmerz: Erste Ergebnisse der Elpis-Studie' wird während der Konferenz, die vom 13. bis 16. April 2025 in Rotterdam, Niederlande, stattfindet, präsentiert. Zu den Autoren der Studie gehören Dr. Robert S. Schwartz, Chief Medical Officer von Autonomix Medical, und Dr. Askar Uktamovich Sabirov vom AKFA Medline Krankenhaus.
- Abstract acceptance at major medical conference (ECIO 2025) validates scientific interest in technology
- Early proof-of-concept study results ready for presentation indicates development progress
- None.
THE WOODLANDS, TX, April 03, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced an abstract detailing its technology and early proof-of-concept study results has been accepted for poster presentation at the 2025 European Conference on Interventional Oncology (ECIO), being held April 13-16, 2025 in Rotterdam, Netherlands.
Details of the poster presentation are as follows:
Title: Catheter-Based Transvascular RF Neural Ablation for Severe Pancreatic Cancer Pain: First Results from The Elpis Study
Authors: Robert S. Schwartz, MD, Chief Medical Officer of Autonomix Medical, Inc, and Askar Uktamovich Sabirov, MD, Primary Investigator, AKFA Medline Hospital
About ECIO 2025
The European Conference on Interventional Oncology (ECIO) is renowned as the most comprehensive platform for interventional oncology education and knowledge sharing - bringing together a growing community of experts from around the world for a multidisciplinary program covering all aspects of Interventional Oncology (IO). The conference will feature an outstanding line-up of more than 140 lectures and 16 hands-on training sessions, which will include highlights on topics such as immuno-oncology, revolutions in HCC treatment, pediatric IO, and much more.
For more information about the ECIO 2025 please visit the conference website.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with up to 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
autonomix@jtcir.com
FAQ
What will Autonomix Medical (AMIX) present at ECIO 2025?
When and where is AMIX scheduled to present their Elpis Study results?
Who are the authors of the AMIX Elpis Study presentation?
What type of treatment technology is AMIX developing for pancreatic cancer?
